Epidemiologic results raise need for better diagnosis, management of XFS

Article

Exfoliation syndrome (XFS) is a global disease that is important to recognize because of its association with other visual-threatening ocular pathologies, said Alan H. Robin, MD, of the Wilmer Eye Institute at Johns Hopkins University in the United States.

Exfoliation syndrome (XFS) is a global disease that is important to recognize because of its association with other visual-threatening ocular pathologies, said Alan H. Robin, MD, of the Wilmer Eye Institute at Johns Hopkins University in the United States.

Speaking at the World Ophthalmology Congress, Dr. Robin presented his data from an epidemiological study of XFS conducted in southern India that illustrated XFS was a risk factor for glaucoma and highly associated with cataract as well as with vision impairment and blindness from those latter disorders. In that study, about 5,500 subjects underwent a thorough eye examination by ophthalmologists who were carefully trained to identify XFS. A diagnosis of XFS was made in about 6% of the population, and among those individuals, about two-thirds had bilateral disease.

In a multivariate adjusted analysis, XFS increased the risk of glaucoma about sixth-fold. In addition, the study found almost 97% of phakic eyes with XFS had an opacified lens, while 132 eyes had prior cataract surgery. The diagnoses of lens opacification and glaucoma were associated with significant vision loss. Presenting vision was impaired (20/60 or worse) in 91% of eyes with XFS, and 51% were bilaterally blind. After best correction, 60% of eyes with XFS had impaired vision and 26% were bilaterally blind. About 90% of the cases of blindness were accounted for by cataract and 10% by glaucoma, and 60% of patients presenting with glaucoma were blind in both eyes.

"Due to the prevalence of glaucoma and cataract among patients with XFS, we have to be much more careful in identifying individuals with this disease. Leaders in this field need to do better in teaching our residents and colleagues in the community that XFS is found in populations worldwide, that patients with XFS and glaucoma need aggressive care and follow-up, and about methods for improving the outcomes of cataract surgery in these eyes so that we do not create even more blindness," said Dr. Robin.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.